• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Single-cycle adjuvant chemotherapy may be effective in stage I testicular cancer

byKhang DinhandDavid Wang
November 14, 2014
in Oncology, Urology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. A single-cycle of adjuvant bleomycin, etoposide, and cisplatin (BEP) after orchiectomy reduces the relapse rate of stage I non-seminomatous germ cell tumors.

2. The single-cycle regimen may have lower relapse rate than retroperitoneal lymph node dissection and less toxicity than the standard 2-cycle regimen.

Evidence Rating Level: 2 (Good)           

Study Rundown: Despite excellent overall cure rates for stage I non-seminomatous germ cell tumors (NSGCT), tumors with pathological findings of vascular invasion (VI) demonstrate a high probability of relapse. In cases of relapse, salvage therapy consisting of 3-4 cycles of bleomycin, etoposide, and cisplatin (BEP) is required but poorly tolerated. The use of adjuvant therapies, such as retroperitoneal lymph node dissection (RPLND) or 2 cycles of modified adjuvant BEP remains controversial in stage I NSGCT cancers with high risk of relapse. RPLND is disadvantaged by its 29% relapse rate, perioperative morbidity, and long-term ejaculatory dysfunction. Two cycles of adjuvant BEP has been shown to be more effective in controlling relapse, but is limited by systemic toxicities and risks of infertility and secondary malignancies. In this phase II study, the efficacy and safety of single-cycle adjuvant BEP was examined. Forty patients with stage I NSGCT were given a single cycle of modified BEP post-orchiectomy and followed for 15 years. At the conclusion of the trial, 1 patient experienced a metastatic relapse, 3 developed contralateral testicular cancers, and 3 developed secondary malignancies. Three patients reported mild tinnitus and 1 suffered peripheral polyneuropathy. These relapse rates are comparable to those achieved with 2 cycles of BEP, with less toxicity. The results support the use of single-cycle adjuvant BEP in stage I NSGCT. However, as a single-arm study, these results do not directly compare the 2 treatment modalities head-to-head. Furthermore, the size of the study may be too small to capture relatively rare, but important, events that occur over a long period of follow-up.

Click to read the study in the Annals of Oncology

Relevant reading: Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report

In-Depth [prospective cohort]: In this single arm, phase II clinical trial, 40 patients with high risk, stage I NSGCT with VI and/or >50% embryonal cell carcinoma components were given a single-cycle of modified BEP within 4 weeks after orchiectomy. Patients were 18-44 years old, with a median age of 33 at the time of surgery. Median follow-up was 186 months and the primary endpoint was relapse, with secondary endpoints of metachronous testicular cancer, secondary malignancy, and late chemotherapy-related toxicity. One patient (2.5%) had a pulmonary relapse after 13 months of follow-up and died despite salvage therapy. Three patients (7.5%) developed metachronous tumors of the contralateral testis; all were successfully treated. Three patients (7.5%) developed colorectal cancer or leukemia. With respect to adverse effects, 3 patients experienced tinnitus after adjuvant therapy and 1 patient treated with salvage BEP for contralateral NSGCT developed peripheral neuropathy.

RELATED REPORTS

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

The 2 Minute Medicine Podcast Episode 2

The Scan by 2 Minute Medicine®: An Organ Donor Crisis, A Closer Look at Bipolar Disorder, What to know about Processed Foods, and Key Issues in Men’s Health

More from this author: Erlotinib does not demonstrate increased survival in ovarian epithelial carcinomas, Afatinib shows increased progression-free survival in non-small-cell lung cancer, New method may predict response to chemotherapy for lung cancer, Escalated-dose radiotherapy did not increase survival in prostate cancer, Stereotactic radiosurgery promising for patients with multiple brain metastases

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: chemotherapynon-seminomatous germ cell tumorsTesticular Cancer
Previous Post

Chronic marijuana use linked to structural differences in the brain

Next Post

Vitamin D deficiency linked to preeclampsia

RelatedReports

No benefit of erlotinib in combined hepatocellular carcinoma treatment
Oncology

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

January 11, 2023
2MM Podcast

The 2 Minute Medicine Podcast Episode 2

November 22, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: An Organ Donor Crisis, A Closer Look at Bipolar Disorder, What to know about Processed Foods, and Key Issues in Men’s Health

November 15, 2022
Increased frailty associated with childhood cancer survivorship
Chronic Disease

United States-based chemotherapy regimen for Ewing sarcoma is more effective and safer than the standard European regimen

November 9, 2022
Next Post
Maternal vitamin D status does not affect offspring’s bone-mineral content

Vitamin D deficiency linked to preeclampsia

25% reoperation risk after breast-conserving lumpectomy

25% reoperation risk after breast-conserving lumpectomy

β-blockers linked to improved survival in preserved ejection fraction heart failure

β-blockers linked to improved survival in preserved ejection fraction heart failure

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options